Clinical trials: Conbercept
Exudative Age-Related Macular Degeneration
Efficacy and Safety of Intravitreal Conbercept With Modified Treat-and-Extend Regimens in Exudative AMD
This is a prospective study. Data from patients diagnosed with nAMD who have never received related treatment were collected. Treatment was an intravitreal injection of 0.5 mg conbercept using modified "T\&E" treatment plans.
- Trial name
- IIT-A (NCT05539235)
- Testing
- different degrees of adjustment of the injection interval
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Age-related Macular Degeneration
Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration
The study will evaluate the efficacy and safety of two different regimens of Conbercept (Treat-and-Extend (T\&E) Regimen vs. Pro Re Nata (PRN)) in patients with wet AMD.
- Trial name
- NCT02802657
- Testing
- Treat-and-Extend regimen, Pro Re Nata, Conbercept
- Where
- 5 sites in China
- Volunteers
- 141 people
- Sponsor
- Xiaodong Sun
Choroid Neovascularization Secondary to Degenerative Myopia
A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV
This study is design to evaluate the effect of conbercept therapy on visual acuity and anatomic outcomes compared to sham injection and durability of response observed in subjects with choroid neovascularization secondary to…
- Trial name
- SHINY (NCT01809223)
- Testing
- conbercept, Fixed, conbercept, PRN
- Where
- 13 sites in China
- Volunteers
- 176 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Diabetic Macular Edema
Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing)
This study is designed to assess safety and efficacy of intravitreal injection of Conbercept on visual acuity and anatomic outcomes in patients with diabetic macular edema (DME) .
- Trial name
- NCT02194634
- Testing
- Conbercept, Laser
- Where
- 17 sites in China
- Volunteers
- 248 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Myopic Choroidal Neovascularisation
Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization
Choroidal neovascularization (CNV) secondary to pathologic myopia (PM-CNV) is a common vision-threatening complication and often affects adults of working age.
- Trial name
- NCT03971162
- Testing
- 3+PRN, 6+PRN
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Choroidal Neovascularization, Uveitis
Conbercept in Choroidal Neovascularization Secondary to Uveitis
The investigators hypothesize that it is safe and effective to treat patients with choroidal neovascularisation (abnormal blood vessels growing under the retina) secondary to uveitis with Conbercept.
- Trial name
- NCT02934841
- Testing
- Conbercept
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Chongqing Medical University
Neovascular Age-related Macular Degeneration
Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)
The purpose of this clinical study is to evaluate the efficacy and safety of two different levels of conbercept intravitreal (IVT) injection as compared to the approved vascular endothelial growth factor (VEGF) antagonist active…
- Trial name
- NCT03630952
- Testing
- 0.5 mg Conbercept Intravitreal Injection, 1.0 mg Conbercept Intravitreal Injection, 2.0 mg Aflibercept Intravitreal Injection
- Where
- 154 sites in United States, Bulgaria and 10 more
- Volunteers
- 1,157 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Polypoidal Choroidal Vasculopathy (PCV)
The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV)
To assess the efficacy of intravitreal injection of 0.5 mg conbercept in patients with polypoidal choroidal vasculopathy (PCV) and explore the optimal route of administration.
- Trial name
- STAR (NCT03159884)
- Testing
- Conbercept
- Where
- 35 sites in China
- Volunteers
- 300 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Circumscribed Choroidal Haemangioma
Application of Intravitreal Conbercept Injection as a Primary Treatment for Exudative Circumscribed Choroidal Haemangioma
The aim of this study was to investigate the safety and effectiveness of application of intravitreal conbercept injection as the primary treatment for exudative circumscribed choroidal haemangioma.
- Trial name
- IVCCCH (NCT03973125)
- Testing
- conbercept
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Proliferative Diabetic Retinopathy
Effect of Postvitrectomy Proactive Use of Conbercept on Postoperative Complications in PDR Patients
This is an unmasking randomized clinical trial. the main purpose of this study is to analyze whether posvitrectomy proactive use of conbercept can reduce the rate of postoperative complication in PDR patients.
- Trial name
- NCT05642793
- Testing
- proactive Anti-VEGF (conbercept) use, passive Anti-VEGF (conbercept) use
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking University Third Hospital
Retinal Vein Occlusion
Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein Occlusion
This is a Phase II, single arm, open label clinical trial. 60 RVO patients (including 30 BRVO and 30 CRVO, respectively) are enrolled in the study.
- Trial name
- FALCON (NCT01809236)
- Testing
- Conbercept
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Uveitis, Macular Edema
Effects of Conbercept in Refractory Uveitic Macular Edema and VEGF
As a primary exploratory study, this study aims to evaluate the short-term effectiveness of intravitreal Conbercept injection in UME, and to explore the correlation between inflammatory factors like VEGF and the responsiveness to…
- Conditions
- Uveitis, Macular Edema, Vascular Endothelial Growth Factor, Effect of Drugs
- Trial name
- NCT04296838
- Testing
- intravitreal injection of Conbercept
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Peking Union Medical College Hospital
Age-Related Macular Degeneration, Polypoidal Choroidal Vasculopathy
Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases
Macular neovascular diseases including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), pathological myopia (PM) and etc. can cause severe vision loss.
- Conditions
- Age-Related Macular Degeneration, Polypoidal Choroidal Vasculopathy, Pathological Myopia, Conbercept
- Trial name
- NCT03128463
- Testing
- Intravitreal injection of conbercept
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Xun Xu
Diabetic Macular Edema
Changes in Optical Coherence Tomography Leakage Mapping in Diabetic Macular Edema After Conbercept Treatment
Eyes with diabetic macular edema requiring conbercept treatment will be followed up for one month. Before treatment, one week after treatment and one month after treatment, the eyes will be examined by optical coherence…
- Trial name
- NCT04254536
- Volunteers
- 35 people
- Sponsor
- Renmin Hospital of Wuhan University
Proliferative Diabetic Retinopathy, Tractional Retinal Detachment
Conbercept Injection in Treatment of Severe Proliferative Diabetic Retinopathy
To evaluate efficacy of different intravitreal Conbercept injection therapy in the treatment of severe proliferative diabetic retinopathy.
- Trial name
- NCT02816710
- Testing
- Conbercept
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Ruijin Hospital
Polypoidal Choroidal Vasculopathy
Initial Versus Delayed PDT Combination With Conbercept in PCV
To compare the initial versus delayed verteporfin photodynamic therapy (PDT) in combination with conbercept in patients with symptomatic polypoidal choroidal vasculopathy (PCV).
- Trial name
- NCT02821520
- Testing
- conbercept, Initial PDT, Delayed PDT
- Where
- 3 sites in China
- Volunteers
- 80 people
- Sponsor
- The Eye Hospital of Wenzhou Medical University
Age-related Macular Degeneration
Head to Head Study of Anti-VEGF Treatment.
An exploratory single site, open label, randomized, controlled study evaluated plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab (Lucentis) and conbercept (Langmu) for neovascular…
- Trial name
- RELIANCE (NCT02577107)
- Testing
- ranibizumab, Conbercept
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Novartis Pharmaceuticals
Retinopathy of Prematurity
Real World Study of the Effectiveness and Safety of Conbercept Ophthalmic Injection in the Treatment of Retinopathy of Prematurity - Multicenter, Retrospective and Observational Study Based on Real World Data
This study is a retrospective, multi-center real world study. The real world data comes from the electronic medical record system and disease database of the research centers .The patient's demographic information, disease…
- Trial name
- NCT04985448
- Where
- 2 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Retinal Vein Occlusion
A Study on the Combination of Tongluo Huayu Formula in Treating RVO of Phlegm-Stasis Intertwinement Type: Based on the Mechanism of Systemic Metabolic Regulation Mediated by Gut Microbiota
The goal of this clinical trial is to evaluate the synergistic efficacy and safety of the Tongluo Huayu Formula combined with conventional Western medical treatment for RVO, thereby providing high-quality evidence to support its…
- Trial name
- NCT07718503
- Testing
- Conbercept Ophthalmic Injection, Tongluo Huayu Formula, Laser Photocoagulation
- Where
- China
- Volunteers
- 80 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Circumscribed Choroidal Haemangioma
Safety and Effectiveness of Intravitreal Conbercept for Exudative Circumscribed Choroidal Haemangioma
This prospective clinical trial aims to evaluate the safety and effectiveness study of intravitreal conbercept injection for exudative circumscribed choroidal haemangioma.
- Trial name
- NCT03571282
- Testing
- conbercept
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University